Patrys (ASX:PAB) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Patrys Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Patrys's annualized Gross Profit for the quarter that ended in Dec. 2024 was A$0.00 Mil. Patrys's average Total Assets over the quarter that ended in Dec. 2024 was A$3.76 Mil. Therefore, Patrys's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.

Patrys Gross-Profit-to-Asset % Historical Data

The historical data trend for Patrys's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Patrys Gross-Profit-to-Asset % Chart

Patrys Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.42

0.31

0.21

Patrys Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Patrys's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Patrys's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Patrys's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Patrys's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Patrys's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Patrys Gross-Profit-to-Asset % Calculation

Patrys's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2024 )	/	( (Total Assets (A: Jun. 2023 )	+	Total Assets (A: Jun. 2024 ))	/ count )
	=	0	/	( (7.524	+	4.162)	/ 2 )
	=	0	/	5.843
	=	0.00 %

Patrys's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	0	/	( (4.162	+	3.353)	/ 2 )
	=	0	/	3.7575
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Patrys Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Patrys's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Patrys Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Patrys Ltd (ASX:PAB) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.patrys.com

Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 PAT-DX1-NP, PAT-DX3, and PAT-LM1. Its main technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody that penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.